In 2004, Californians voted to create the California Institute for Regenerative Medicine (CIRM) and to allocate US$3 billion to stem-cell research in the state. Eleven years on, the institute has unveiled plans for 'CIRM 2.0'. Randy Mills, the recently appointed head of CIRM and former head of stem-cell company Osiris Therapeutics, hopes an organizational overhaul will speed the development of stem-cell therapeutics as the agency starts spending its last $900 million. He speaks with Asher Mullard about the changes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Randy Mills. Nat Rev Drug Discov 14, 86–87 (2015). https://doi.org/10.1038/nrd4538
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4538
